ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly cardiovascular therapeutic area — Worldwide revenue ($M) [legacy grouping through FY2018] ($M)
Form 10-K Segment & Disaggregated Revenue Note (legacy Cardiovascular grouping)
Latest, Q3 2018
584
Period ended Sep 30, 2018
Change on a year earlier
-11.9%
663 in Q3 2017
History
21 quarters
Since Q2 2012
Sources
16
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Cardiovascular therapeutic area — Worldwide revenue ($M) [legacy grouping through FY2018] ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2018 | Sep 30, 2018 | 584 | -11.9% | Form 10-Q (filed 2018-11-06) ↗ |
| Q2 2018 | Jun 30, 2018 | 693 | -14.7% | Form 10-Q (filed 2018-07-25) ↗ |
| Q1 2018 | Mar 31, 2018 | 562 | -19.5% | Form 10-Q (filed 2018-04-27) ↗ |
| Q4 2017 | Dec 31, 2017 | 699 | – | Form 10-K (filed 2018-02-20) ↗ |
| Q3 2017 | Sep 30, 2017 | 663 | – | Form 10-Q (filed 2018-11-06) ↗ |
| Q2 2017 | Jun 30, 2017 | 812 | – | Form 10-Q (filed 2018-07-25) ↗ |
| Q1 2017 | Mar 31, 2017 | 697 | -7.6% | Form 10-Q (filed 2018-04-27) ↗ |
| Q1 2016 | Mar 31, 2016 | 754 | +5.5% | Form 10-Q (filed 2016-04-29) ↗ |
| Q4 2015 | Dec 31, 2015 | 830 | +1.4% | Form 10-K (filed 2016-02-19) ↗ |
| Q3 2015 | Sep 30, 2015 | 760 | +0.4% | Form 10-Q (filed 2015-10-30) ↗ |
| Q2 2015 | Jun 30, 2015 | 763 | -0.3% | Form 10-Q (filed 2015-07-30) ↗ |
| Q1 2015 | Mar 31, 2015 | 715 | +0.3% | Form 10-Q (filed 2015-04-30) ↗ |
| Q4 2014 | Dec 31, 2014 | 818 | – | Form 10-K (filed 2015-02-19) ↗ |
| Q3 2014 | Sep 30, 2014 | 757 | – | Form 10-Q (filed 2014-10-29) ↗ |
| Q2 2014 | Jun 30, 2014 | 765 | +4.6% | Form 10-Q (filed 2014-07-28) ↗ |
| Q1 2014 | Mar 31, 2014 | 713 | +2.7% | Form 10-Q (filed 2014-04-28) ↗ |
| Q2 2013 | Jun 30, 2013 | 731 | +13.0% | Form 10-Q (filed 2013-07-26) ↗ |
| Q1 2013 | Mar 31, 2013 | 694 | – | Form 10-Q (filed 2014-04-28) ↗ |
| Q4 2012 | Dec 31, 2012 | 696 | – | Form 10-K (filed 2014-02-19) ↗ |
| Q3 2012 | Sep 30, 2012 | 651 | – | Form 10-Q (filed 2013-10-30) ↗ |
| Q2 2012 | Jun 30, 2012 | 647 | – | Form 10-Q (filed 2013-07-26) ↗ |
Breakdown
What makes up cardiovascular therapeutic area — worldwide revenue ($m) [legacy grouping through fy2018]
Cite this data
StockData. (2026). Eli Lilly Cardiovascular therapeutic area — Worldwide revenue ($M) [legacy grouping through FY2018] ($M), quarterly Q2 2012–Q3 2018 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/ta_cardiovascular_ww_legacy
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.